Welcome to our dedicated page for MAIA Biotechnology news (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.
MAIA Biotechnology, Inc. (NYSE American: MAIA) is a clinical-stage biopharmaceutical company whose news flow is closely tied to the development of ateganosine (THIO), a first-in-class telomere-targeting therapy for advanced non-small cell lung cancer (NSCLC). News about MAIA often centers on clinical milestones, regulatory designations, and financing activities that support its oncology programs.
Investors and observers following MAIA’s news can expect regular updates on its Phase 2 THIO-101 and Phase 3 THIO-104 trials. These items include announcements of first patient dosing, expansion into new countries, enrollment progress, and presentations of trial-in-progress posters at major conferences such as the Society for Immunotherapy of Cancer (SITC), the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, and the European Society for Medical Oncology (ESMO) Congress.
MAIA’s press releases, many of which are furnished via Form 8-K filings, also highlight regulatory developments such as the U.S. FDA Fast Track designation for ateganosine in NSCLC and Orphan Drug Designations in additional tumor types. Another recurring theme in the company’s news is insider activity: open-market share purchases by the CEO and directors, and participation by board members in private placement financings, which the company frames as signals of confidence in the ateganosine platform.
On this news page, readers can review MAIA’s announcements related to clinical data signals, trial design details, international site activations, and capital raises that fund key study steps. For those tracking the progress of telomere-targeting approaches in oncology and the later-line NSCLC treatment landscape, MAIA’s news provides an ongoing record of how its investigational therapy is advancing through mid- to late-stage clinical development.
MAIA Biotechnology (NYSE: MAIA) provided a corporate update on Jan 20, 2026 outlining 2025 achievements and targeted 2026 clinical milestones for ateganosine, a telomere-targeting immunotherapy. Key 2025 items include FDA Fast Track designation, initiation of a pivotal THIO-104 Phase 3 in 3L NSCLC, Part C expansion of the THIO-101 Phase 2 into Asia and Europe, a $2.3M NIH grant, strategic combination agreements with Roche and BeOne, and ~$17.6M capital raised in 2025. MAIA cites strong 2025 efficacy data and a projected 18–24 month path toward potential early commercial approval, with planned interim Phase 3 efficacy readouts and continued FDA engagement in 2026.
MAIA (NYSE American: MAIA) announced that independent directors participated in a private placement that closed on December 22, 2025, with three directors buying a total of 179,737 shares and 179,737 warrants at an average price of $1.224.
Gross proceeds from the offering were approximately $1.51 million. Directors and officers now hold 5,019,857 shares, equal to 13.43% of MAIA. The company said the financing reflects confidence in ateganosine, its first-in-class anticancer therapy; MAIA launched a pivotal Phase 3 international trial in December 2025 and the FDA granted Fast Track designation for ateganosine in NSCLC.
MAIA Biotechnology (NYSE American: MAIA) entered definitive agreements for a private placement of 1,233,488 shares of common stock at $1.224 per share and accompanying warrants to buy one share at an exercise price of $1.36.
The warrants become exercisable six months after issuance, expire three years from issuance, and the offering is expected to close on or about December 18, 2025. Gross proceeds are expected to be approximately $1.51 million prior to offering expenses. The company intends to use net proceeds to fund Step 1 of Part C of the Phase II THIO-101 trial and for working capital.
MAIA (NYSE American: MAIA) announced initiation of a pivotal Phase 3 trial for ateganosine on Dec 11, 2025, following ongoing Phase 2 data described as surpassing expectations in advanced non‑small cell lung cancer (NSCLC). The U.S. FDA has granted Fast Track designation for ateganosine in NSCLC. The company describes ateganosine as a first‑in‑class, direct telomere‑targeting agent with a dual mechanism that combines telomere disruption and immune activation via cGAS/STING and T‑cell responses.
Management cited statistical assessments indicating a very high probability of technical success for regulatory approval; Phase 3 outcomes are now the next milestone for potential commercialization.
MAIA (NYSE:MAIA) announced the first patient dosing in the THIO-104 Phase 3 pivotal trial of ateganosine given in sequence with a checkpoint inhibitor (CPI) as a third-line treatment for advanced non-small cell lung cancer (NSCLC).
The multicenter, open-label trial will randomize up to 300 patients 1:1 to ateganosine+CPI versus investigator’s choice chemotherapy, with overall survival as the primary endpoint. MAIA has regulatory approval to screen in Taiwan, Turkey, select EMA countries, and Georgia; screening and enrollment are underway.
Supporting data cited: prior THIO-101 observed PFS 5.6 months versus ~2.5 months standard of care, one patient reached 30 months survival, and the FDA has granted Fast Track designation for ateganosine in NSCLC.
MAIA (NYSE American: MAIA) reported additional insider open-market purchases and highlighted clinical progress for its small-molecule telomere-targeting therapy ateganosine.
Directors and officers acquired approximately 182,445 shares between Nov 21–28, 2025, and continue to hold 4,480,120 shares (12.95%) of the company. The company said ateganosine is advancing through mid‑ to late‑stage development with encouraging clinical signals in advanced non‑small cell lung cancer (NSCLC).
MAIA (NYSE:MAIA) announced progress for its telomere-targeting candidate ateganosine as a potential new class for advanced non-small cell lung cancer (NSCLC) on Dec 10, 2025. MAIA said ateganosine has received FDA Fast Track designation for NSCLC patients resistant to immunotherapy and chemotherapy and that it is initiating a Phase 3 THIO-104 trial.
The release highlights market context and figures: the CPI category generated about $50B in 2024, NSCLC market value cited at $34.1B now and projected to $68.8B by 2033, ~180,000 U.S. NSCLC patients entering treatment annually, and Keytruda revenue of $29.5B in 2024. Ateganosine also holds FDA orphan drug designations for glioblastoma, HCC, and SCLC, each conferring seven years of U.S. exclusivity if approved.
MAIA Biotechnology (NYSE American: MAIA) announced that the CEO and certain directors purchased approximately 182,445 shares of MAIA common stock in open-market trades between November 21 and 28, 2025 at an average price of $1.06 per share. Vlad Vitoc, chairman and CEO, purchased 94,300 shares at an average of $1.08, while directors Cristian Luput and Stan V. Smith purchased a combined 88,145 shares at an average of $1.04.
The company highlighted clinical progress for ateganosine in its Phase 2 THIO-101 trial, reporting a 38% response rate and 17.8 months overall survival to date.
MAIA (NYSE American: MAIA) reported clinical updates for its telomere‑targeting agent ateganosine at SITC 2025. The company confirmed 12 patients enrolled in the Phase 2 THIO-101 expansion (Part C) with enrollment active in EMA countries including Hungary and Poland, plus screening in Turkey and Taiwan. MAIA has begun screening patients in the Phase 3 THIO-104 trial. The FDA has granted Fast Track designation for ateganosine in NSCLC. MAIA reported an observed overall survival (OS) of 17.8 months in THIO-101 to date and a single patient with 912 days (30 months) survival as of September 17, 2025. Posters for THIO-101 and THIO-104 were filed on Form 8-K and posted on the company website on November 7, 2025.
MAIA Biotechnology (NYSE:MAIA) announced that its CEO presented at Smart Diaspora 2025 and that Romania has begun screening patients for the Phase 2 THIO-101 Part C expansion evaluating ateganosine sequenced with an immune checkpoint inhibitor as a third-line treatment for non-small cell lung cancer (NSCLC).
The company highlighted an observed 38% response rate from its treatment in third-line NSCLC versus current third-line responses of up to 6%, and noted it is pursuing accelerated approval in the U.S. following an FDA Fast Track designation received in July. Romanian investigators and a key local investigator, Tudor Ciuleanu MD PhD, will support the expansion.
FAQ
What is the current stock price of MAIA Biotechnology (MAIA)?
What is the market cap of MAIA Biotechnology (MAIA)?
